Literature DB >> 19175607

Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene.

Simone Merlin1, Stefano Pietronave, Deborah Locarno, Guido Valente, Antonia Follenzi, Maria Prat.   

Abstract

The c-MET proto-oncogene, encoding the p190 hepatocyte growth factor tyrosine kinase receptor, can acquire oncogenic potential by multiple mechanisms, such as gene rearrangement, amplification and overexpression, point mutation, and ectopic expression, all resulting in its constitutive activation. Hepatocyte growth factor receptor truncated forms are generated by post-translational cleavage: p140 and p130 lack the kinase domain and are inactive. Their C-terminal remnant fragments are generally undetectable in normal cells, but a membrane-associated truncated form is recognized by anti-C-terminus antibodies in some human tumors, suggesting that a hepatocyte growth factor receptor lacking the ectodomain, but retaining the transmembrane and intracellular domains (Met-EC-), could acquire oncogenic properties. Herein we show that NIH-3T3 cells transduced with MET-EC- expressed a membrane-associated constitutively tyrosine-phosphorylated 60-kDa protein and, similarly to NIH-3T3 cells expressing the cytosolic oncoprotein Tpr-Met, showed activated extracellular regulated kinase 1/2 mitogen-activated protein kinase and Akt downstream transducers. Compared to control NIH-3T3 cells, NIH-3T3-Met-EC- cells grew faster and showed anchorage-independent growth and invasive properties in all aspects similar to cells expressing the transforming TPR-MET. Nude female mice injected subcutaneously with NIH-3T3-Met-EC- cells developed visible tumors, displaying the typical morphology of carcinomas with polygonal cells, in contrast to sarcomas with spindle-shaped cells induced by the injection of NIH-3T3-Tpr-Met cells. It is suggested that the different subcellular localization of the oncoproteins, more than differences in signal transduction, could be responsible for the tumor phenotype. All together, these data show that deletion of the ectodomain activates the hepatocyte growth factor receptor and its downstream signaling pathways, unleashing its transforming, invasive, and tumorigenic potential.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19175607     DOI: 10.1111/j.1349-7006.2008.01079.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  12 in total

1.  Structural Basis of TPR-Mediated Oligomerization and Activation of Oncogenic Fusion Kinases.

Authors:  Kuntal Pal; Abhishek Bandyopadhyay; X Edward Zhou; Qingping Xu; David P Marciano; Joseph S Brunzelle; Smitha Yerrum; Patrick R Griffin; George Vande Woude; Karsten Melcher; H Eric Xu
Journal:  Structure       Date:  2017-05-18       Impact factor: 5.006

2.  Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase.

Authors:  Qi Ma; Kun Zhang; Sunny Guin; Yong-Qing Zhou; Ming-Hai Wang
Journal:  Mol Cancer       Date:  2010-11-29       Impact factor: 27.401

3.  Alteration status and prognostic value of MET in head and neck squamous cell carcinoma.

Authors:  Yoon Ah Cho; Eun Kyung Kim; Su Jin Heo; Byoung Chul Cho; Hye Ryun Kim; Ji Myung Chung; Sun Och Yoon
Journal:  J Cancer       Date:  2016-10-25       Impact factor: 4.207

Review 4.  Physiological Signaling and Structure of the HGF Receptor MET.

Authors:  Gianluca Baldanzi; Andrea Graziani
Journal:  Biomedicines       Date:  2014-12-31

5.  Short-form Ron is a novel determinant of ovarian cancer initiation and progression.

Authors:  Katherine M Moxley; Luyao Wang; Alana L Welm; Magdalena Bieniasz
Journal:  Genes Cancer       Date:  2016-05

6.  MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering.

Authors:  Rémi Montagne; Anne Baranzelli; Ghaffar Muharram; Leroy Catherine; Marie Lesaffre; Audrey Vinchent; Zoulika Kherrouche; Elisabeth Werkmeister; Alexis B Cortot; David Tulasne
Journal:  Oncotarget       Date:  2017-02-14

Review 7.  c-Met expression and activity in urogenital cancers - novel aspects of signal transduction and medical implications.

Authors:  Ralf Hass; Susanne Jennek; Yuanyuan Yang; Karlheinz Friedrich
Journal:  Cell Commun Signal       Date:  2017-02-17       Impact factor: 5.712

8.  Isolation and characterization of a spontaneously immortalized multipotent mesenchymal cell line derived from mouse subcutaneous adipose tissue.

Authors:  Andrea Zamperone; Stefano Pietronave; Simone Merlin; Donato Colangelo; Gabriella Ranaldo; Enzo Medico; Federica Di Scipio; Giovanni Nicolao Berta; Antonia Follenzi; Maria Prat
Journal:  Stem Cells Dev       Date:  2013-08-09       Impact factor: 3.272

9.  The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation.

Authors:  K Miekus; E Lukasiewicz; D Jarocha; M Sekula; G Drabik; M Majka
Journal:  Cell Death Dis       Date:  2013-01-17       Impact factor: 8.469

10.  Single-molecule photobleaching reveals increased MET receptor dimerization upon ligand binding in intact cells.

Authors:  Marina S Dietz; Daniel Haße; Davide M Ferraris; Antonia Göhler; Hartmut H Niemann; Mike Heilemann
Journal:  BMC Biophys       Date:  2013-06-03       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.